Vimpat 10 mg/ml solution for infusion
Authorisation EU/1/08/470/16 · UCB Pharma S.A.
- Licence holder
- UCB Pharma S.A. (all products →)
- Active substance
- Lacosamide
- Clinical trials
- 3 clinical trials →
- Dosage form
- Solution for infusion
- Route of administration
- Intravenous use
- ATC codes
- N03AX, N03AX18
- First authorised
- 29/08/2008
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Lacosamide: supply and approvals
30 authorised products on the HPRA list contain Lacosamide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 20 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 470. It has been authorised for 18 years (since 29 August 2008). The HPRA list does not say whether it is on sale.
Other medicines with Lacosamide in Ireland
29 other products on the HPRA list contain Lacosamide, from 7 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Lacosamide Krka 100 mg film-coated tablets | KRKA, d.d., Novo mesto | National authorisation (PA) | Marketed |
| Lacosamide Krka 150 mg film-coated tablets | KRKA, d.d., Novo mesto | National authorisation (PA) | Marketed |
| Lacosamide Krka 200 mg film-coated tablets | KRKA, d.d., Novo mesto | National authorisation (PA) | Marketed |
| Lacosamide Krka 50 mg film-coated tablets | KRKA, d.d., Novo mesto | National authorisation (PA) | Marketed |
| 10 mg/ml Solution for infusion | UCB Pharma S.A. | Centralised EU authorisation | Not stated |
| Lacosamide Accord 10 mg/ml solution for infusion | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Lacosamide Accord 100 mg film coated tablets | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Lacosamide Accord 150 mg film coated tablets | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Lacosamide Accord 200 mg film coated tablets | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Lacosamide Accord 50 mg film coated tablets | Accord Healthcare S.L.U. | Centralised EU authorisation | Not stated |
| Lacosamide Adroiq 10 mg/ml solution for infusion | Extrovis EU Kft. | Centralised EU authorisation | Not stated |
| Lacosamide Ascend 10 mg/ml syrup | Ascend GmbH | National authorisation (PA) | Not marketed |
Other substances in ATC group N03AX
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 11 other active substances share the group N03AX with this product:
Pregabalin (34) · Levetiracetam (31) · Lamotrigine (26) · Topiramate (10) · Perampanel (7) · Cenobamate (5) · Stiripentol (4) · Zonisamide (3) · CANNABIDIOL (1) · Fenfluramine hydrochloride (1) · Ganaxolone (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
UCB Pharma S.A. holds 42 products on the HPRA list, with 13 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.